OncoMatch/Clinical Trials/NCT07778316
Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)
Is NCT07778316 recruiting? Yes, currently enrolling (Sep 2026). This Phase 3 trial studies Tarlatamab for small cell lung cancer.
Treatment: Tarlatamab — The primary objective of this study is to demonstrate non-inferiority in pharmacokinetic (PK) parameters of subcutaneous (SC) vs intravenous (IV) tarlatamab administration and to characterize the efficacy, safety, and tolerability of SC tarlatamab in participants with relapsed extensive-stage small-cell lung cancer (ES-SCLC) after platinum-based chemotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Small Cell Lung Cancer
Disease stage
Required: Stage IV
Extensive-Stage Small Cell Lung Cancer; Measurable disease as defined per RECIST 1.1
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: platinum-based chemotherapy — first-line SCLC
Participants who progressed or recurred following 1 platinum-based regimen.
Cannot have received: systemic anticancer therapy for SCLC
Exception: More than 1 prior line of anticancer therapy for SCLC
More than 1 prior line of anticancer therapy for SCLC
Cannot have received: immune-mediated therapy
Prior history of severe or life-threatening events from any immune-mediated therapy.
Cannot have received: anticancer therapy for a malignancy other than SCLC
Receiving another anticancer therapy for a malignancy other than SCLC.
Cannot have received: tarlatamab or selective inhibitor of the delta-like ligand 3 (DLL3) pathway
Participation in a tarlatamab clinical trial or prior therapy with any selective inhibitor of the delta-like ligand 3 (DLL3) pathway.
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Cancer and Hematology Centers of Western Michigan · Grand Rapids, Michigan
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07778316 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic anticancer therapy for SCLC, immune-mediated therapy, anticancer therapy for a malignancy other than SCLC disqualifies patients from enrollment.
What disease stage is eligible?
Stage IV is required.
Is there an age limit?
Yes. Patients must be 99 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages